Compare EPC & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | ABUS |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.1M | 952.0M |
| IPO Year | 2000 | N/A |
| Metric | EPC | ABUS |
|---|---|---|
| Price | $17.10 | $4.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $23.17 | $5.00 |
| AVG Volume (30 Days) | 730.6K | ★ 1.3M |
| Earning Date | 02-09-2026 | 11-13-2025 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $2,223,500,000.00 | $14,606,000.00 |
| Revenue This Year | $2.81 | $125.30 |
| Revenue Next Year | $1.66 | N/A |
| P/E Ratio | $32.38 | ★ N/A |
| Revenue Growth | N/A | ★ 116.64 |
| 52 Week Low | $15.88 | $2.71 |
| 52 Week High | $34.73 | $5.10 |
| Indicator | EPC | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 54.59 |
| Support Level | $17.23 | $4.42 |
| Resistance Level | $18.50 | $4.70 |
| Average True Range (ATR) | 0.55 | 0.22 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 43.71 | 48.68 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Wet Shave products include razor handles and refillable blades, disposable shave products, and shaving gels and creams. Sun and Skin Care consists of sun care products, men's and women's grooming products, Billie women's grooming products and personal wipe products. Feminine Care products include tampons, pads and liners. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.